41 results about "Mesothelioma" patented technology

A specific antibody and an antigen binding fragment thereof against a CD228 protein, used for testing and treating multiple tumors, such as melanoma, mesothelioma, and colorectal cancer. An antibody binding fragment facilitates the diagnosis and treatment of cancer by specifically binding to CD228. The present invention further comprises antibody-drug conjugates (ADCs) in which drugs bind to antibodies by means of linkers, aiming to improve the treatment effect and reduce the impact on normal cells. Additionally, the present invention provides a nucleic acid encoding an antibody or an antigen binding fragment thereof, so as to produce a recombinant antibody or fragment. In addition, the present invention further provides a kit, used for laboratory research, clinical diagnosis and treatment effect monitoring, facilitating determination of whether tissues or cells express CD228, providing a new strategy for personalized and accurate treatment of cancer.

This disclosure is directed to two cancer-associated fibroblast (CAP) subtypes, namely permissive (permCAF) and restraining (restCAF), in pancreatic ductal adenocarcinoma (PDAC), mesothelioma, urothelial carcinoma, or renal cell carcinoma. Methods are disclosed that describe how to identify a tumor sample as a perCAF or a restCAF subtypes. Methods are also disclosed that use the subtypes for diagnosis, prognosis, differential treatment, and treatment.

The invention relates to a specific antibody aiming at CD228 protein and an antigen binding fragment thereof, which are used for detecting and treating various tumors, such as melanoma, mesothelioma, colorectal cancer and the like. The antibody binding fragment is helpful for diagnosis and treatment of cancers through specific binding with CD228. The invention further comprises antibody drug conjugates (ADCs) which bind a drug to an antibody through a linker, so as to improve the therapeutic effect and reduce the influence on normal cells. Meanwhile, nucleic acids encoding the antibodies or antigen-binding fragments thereof are provided to produce recombinant antibodies or fragments. Besides, the invention also provides a kit which is used for laboratory research, clinical diagnosis and treatment effect monitoring, is beneficial to determining whether tissues or cells express CD228 or not, and provides a new strategy for personalized and precise treatment of cancers.

The present invention relates to therapeutic treatment of cancer, particularly mesothelioma, using Compound IA as single agent or in combination therapy using Compound IA and atezolizumab.

Provided is a therapeutic agent for malignant mesothelioma and a method for selecting a patient with malignant mesothelioma that expresses a large amount of oxytocin receptor. The therapeutic agent for malignant mesothelioma contains a compound that targets the oxytocin receptor as an active ingredient, thereby solving the problem.

The invention relates to a tricyclic heterocyclic compound as well as a preparation method and medical application thereof. Specifically, the invention relates to a compound shown in a general formula (I), a preparation method of the compound, a pharmaceutical composition containing the compound and application of the compound as an MAT2A inhibitor. The compound and the pharmaceutical composition containing the compound can be used for treating and / or preventing diseases related to MAT2A activity, such as mesothelioma, neuroblastoma, rectal cancer, colon cancer, esophageal cancer and the like. Wherein the definition of each group in the general formula (I) is the same as that in the specification.

The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumours and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.

Disclosed herein are methods of administering thiostrepton with anti-cancer agents to treat cancers such as mesothelioma, lung cancer and ovarian cancer.

The present invention relates to the compound 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological pathologies including grade IV glioblastoma with native IDH, grade 3 glioma, embryonal tumour, pituitary tumour, meningioma, haemangiopericytoma, haemangioblastoma, mesothelioma, bile duct adenocarcinoma, exocrine pancreatic cancer, neuroendocrine pancreatic cancer, rectal cancer, urachal cancer, adenocarcinoma of the bladder and oesophageal cancer, and for the treatment of neuropathic pain caused by diabetic peripheral neuropathy, spinal cord injury, post-herpetic neuralgia, chemotherapeutic agent, antitumour agent, cancer, fibromyalgia or hepatitis. The present invention also relates to the pharmaceutical composition comprising 2-hydroxy-octadecene-9-cis-oate.

The disclosure provides binding agents (e.g., antibodies) against a human Hepatitis A virus cellular receptor 2 protein (TIM3), as well as kits and methods for using the same (e.g., immunoassays) as part of a companion diagnostic and for other applications. In some aspects, the binding agents described herein may be used in assays for detecting Non-Small Cell Lung Cancer (NSCLC) and / or other types of lung cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatocellular Carcinoma (HCC) or other types of liver cancer, Renal cell carcinoma, malignant melanoma, gastro-intestinal cancer, colorectal cancer, urothelial carcinoma and other types of bladder cancer, mamma carcinoma and / or other types of breast cancer, ovarian cancer, cervical cancer, prostate cancer, pancreatic cancer, lymphoma / leukemia, malignant mesothelioma, or a cancer in another organ or cell type.

Disclosed herein are novel compounds that are Mpsl / TTK inhibitors. Also disclosed are compositions comprising the compounds and methods of using the compounds in treating various diseases. In some embodiments, some such compounds, compositions, and their uses may be useful for the treatment of cancer. In some implementations, the cancer is brain cancer, glioblastoma multiforme, head and neck cancers, colorectal cancer, stomach or gastric cancer, pancreatic cancer, melanoma, bladder cancer, kidney cancer, renal cell carcinoma, breast cancer, ovarian cancer, lymphoma, thyroid cancer, mesothelioma, sarcoma, lung cancer, non-small cell lung cancer, small cell lung cancer, or endometrial cancer.

Embodiments provided herein relate to methods and compositions for treating mesothelioma and / or a small cell lung cancer that express midkine.

Provided herein are compounds and pharmaceutical compositions containing these compounds useful in the treatment of cancer, such as mesothelioma. In addition, provided herein are methods of treating cancer, such as mesothelioma, using these compounds or pharmaceutical compositions. Specific cancers include cancers mediated by YAP / TAZ, or cancers regulated by the interaction between YAP / TAZ and TEAD, such as mesothelioma.

This document provides methods and materials involved in assessing and / or treating a mammal (e.g., a human) having cancer. For example, methods and materials that can be used to identify a cancer as being likely to respond to one or more immune checkpoint inhibitors are provided. For example, methods and materials that can be used to identify a mammal having cancer as being likely to develop one or more immune-related adverse events (irAEs) are provided. Methods for treating a mammal (e.g., a human) having cancer (e.g., lung cancer such as mesothelioma) where the cancer treatment is selected based on whether or not the cancer is likely to be responsive to one or more immune checkpoint inhibitors and / or whether or not the mammal is likely to develop one or more irAEs are also provided.

To provide a treatment for malignant mesothelioma that can specifically kill cancer cells and has few side effects. [Solution] A therapeutic agent for malignant mesothelioma comprising cerurenin and / or its derivatives, or KN-93 and / or its derivatives, as an active ingredient.

This invention relates to the field of medicinal chemistry, and particularly to a small molecule inhibitor of TEAD and its use in drugs for TEAD receptor-related cancers. Seven compounds were identified as TEAD inhibitors through virtual screening, and one compound was ultimately determined to have inhibitory effects on TEAD cells. This compound can therefore serve as a lead compound for the preparation of drugs for treating mesothelioma and other diseases related to the TEAD target. Specifically, the compound is: N-(4-fluorophenyl)-6-methyl-2-[5-methyl-1-(4-methylphenyl)pyrazol-4-yl]quinoline-4-carboxamide. This invention effectively screens ligands that inhibit the TEAD receptor using a combination of the AutoGen software for automated molecule generation and bioactivity assays. These ligands can serve as lead compounds for the preparation of drugs for treating TEAD receptor-mediated diseases, especially mesothelioma, and can effectively treat TEAD receptor-related diseases and their complications.

The application discloses a histone deacetylase 6 inhibitor and application thereof, and belongs to the technical field of chemical medicines. The inhibitor is the following compound or pharmaceutically acceptable salt thereof: which can be used for the treatment of lung cancer, melanoma, liver cancer, kidney cancer, leukemia, non-small cell lung cancer, prostate cancer, thyroid cancer, skin cancer, pancreatic cancer, ovarian cancer, testicular cancer, breast cancer, bladder cancer, gallbladder cancer, myelodysplastic syndrome, lymphoma, esophageal cancer, thyroid follicular cancer, gastrointestinal cancer, tumors of the central or peripheral nervous system, mesothelioma, type II or non-insulin-dependent diabetes, and autoimmune diseases.

This document provides to methods and materials involved in assessing and / or treating a mammal (e.g., a human) having cancer (e.g., mesothelioma). For example, methods and materials provided herein can be used to identify a cancer (e.g., a mesothelioma) as being likely to respond to one or more immune checkpoint inhibitors. For example, methods and materials provided herein can be used to treat a mammal (e.g., a human) having cancer (e.g., mesothelioma) where the cancer treatment is selected based on whether or not the cancer is likely to be responsive to one or more immune checkpoint inhibitors.

The present invention relates to a tricyclic heterocyclic compound, a preparation method therefor and a pharmaceutical use thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof as a PRMT5 inhibitor. The compound and the pharmaceutical composition containing the compound can be used for treating and / or preventing diseases related to PRMT5 activity, such as non-small cell lung cancer, mesothelioma, neurofibrosarcoma, pancreatic cancer, and solid tumor. The definition of each group in the general formula (I) is the same as that in the description.

The present invention relates to a method for diagnosing or treating cancer using cancer-related fibroblasts. According to the method according to the present invention, cancer, particularly breast cancer and pancreatic cancer, can be more accurately diagnosed by using AKR1C1+ inflammatory fibroblasts and / or mesothelioma-derived fibroblasts, and early treatment is possible on the basis thereof. Thus, the method is expected to be widely used in the medical field.

Provided herein are compounds and pharmaceutical compositions containing the compounds that are useful for treating cancer, such as mesothelioma. Also, provided herein are methods of using the compounds or the pharmaceutical compositions for treating cancer, such as mesothelioma. Specific cancers include those that are mediated by YAP / TAZ or those that are modulated by the interaction between YAP / TAZ and TEAD, such as mesothelioma.

Provided herein are methods of treating cancer (e.g., ovarian, mesothelioma, triple-negative breast cancer), which comprise administering to a human patient in need thereof: (a) a PD-1 antagonist; (b) an ILT4 antagonist; and (c) one or more chemotherapeutic agents. Also provided are pharmaceutical compositions and kits containing such agents for the treatment of cancer.

The invention belongs to the field of cell culture, and relates to a mesothelioma organoid culture composition, the mesothelioma organoid culture composition comprises Rspondin-1, Noggin, Y27632, a growth factor and glutamic acid or a derivative thereof, the mesothelioma organoid culture composition is simple in component and reasonable in collocation, the mesothelioma organoid culture composition is combined with a specific culture method, mesothelioma cells from thoracic / peritoneum can be rapidly cultured, and the mesothelioma organoid culture composition is suitable for large-scale production. And mesothelioma organs with physiological characteristics are generated.

Disclosed herein are novel compounds that are Mpsl / TTK inhibitors. Also disclosed herein are compositions comprising the compounds and methods of using the compounds in treating various diseases in a patient. In some embodiments, some such compounds, compositions, and their uses may be useful for the treatment of cancer. In some implementations, the cancer is brain cancer, glioblastoma multiforme, head and neck cancers, colorectal cancer, stomach or gastric cancer, pancreatic cancer, melanoma, bladder cancer, kidney cancer, renal cell carcinoma, breast cancer, ovarian cancer, lymphoma, thyroid cancer, mesothelioma, sarcoma, lung cancer, non-small cell lung cancer, small cell lung cancer, or endometrial cancer.

This invention provides a stable passaged human mesothelioma cell line MESO-016, its construction method, and its application in tumor research and drug development. The cell line provided by this invention can be continuously passaged in vitro and possesses xenogeneic tumorigenesis ability. Tumors formed in nude mice exhibit the same pathological characteristics as the primary tumor tissue, making it suitable as a cell material for research on mesothelioma-related drugs and diagnostic reagents, as well as for studying the mechanisms of tumor development and progression.

There is provided A compound of formula I, a salt or solvate thereof as described herein, for treating MYC positive cancers including lung cancer, leukemia, breast cancer, myeloproliferative disorders, colorectal cancer, medulloblastoma, renal, hepatocellular cancer, melanoma, ovarian cancer, prostate cancer, esophageal adenocarcinoma, liposarcoma, esophageal squamous cancer, gastrointestinal stromal tumor, glioma, myxofibrosarcoma, leiomyosarcoma, neuroblastoma, synovial sarcoma, mesothelioma, gastric cancer, thyroid cancer, lymphoma, osteosarcoma, rhabdomyosarcoma, fibrosarcoma, epithelial cancer, and neural cancer.

Provided herein are nucleic acid constructs comprising a polynucleotide sequence encoding a TUSC2 protein. Also contemplated are non-viral and viral vectors comprising nucleic acid constructs disclosed herein. Non-viral vectors include, but are not limited, to DOTAP:cholesterol liposomes. Further contemplated herein are pharmaceutical compositions comprising the nucleic acid constructs or vectors disclosed herein and methods of using the nucleic acid constructs, vectors, or pharmaceutical compositions for the treatment of mesothelioma in a subject in need thereof. These methods can further include administering an additional anti-cancer therapy to the subject in need thereof.

The present invention addresses the issue of providing a malignant mesothelioma therapeutic agent and a method for selecting malignant mesothelioma patients. The issue can be solved by a malignant mesothelioma therapeutic agent that includes, as an effective component thereof, a compound that targets the oxytocin receptor.

The invention relates to a pharmaceutical composition for treating pancreatic cancer. The present invention relates to a method for treating pancreatic cancer comprising administering to a patient in need thereof a CD40 agonist in combination with dendritic cells loaded with mesothelioma cell lysates. Another aspect of the invention relates to dendritic cells loaded with mesothelioma cell lysates for use in the treatment of pancreatic cancer. A last aspect of the invention relates to a pharmaceutical composition comprising such loaded dendritic cells.

The present invention relates to the compound 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological conditions including grade IV glioblastoma, grade 3 glioma, embryonal tumor, pituitary tumor, meningioma, hemangiopericytoma, hemangioblastoma, mesothelioma, cholangiocarcinoma, exocrine pancreatic cancer, neuroendocrine pancreatic cancer, rectal cancer, urinary tract cancer, bladder adenocarcinoma, and esophageal cancer, as well as for use in the treatment of peripheral diabetic neuropathy, spinal cord injury, postherpetic neuralgia, chemotherapeutic agents, antitumor agents, cancer, fibromyalgia, or neuropathic pain caused by hepatitis. The present invention also relates to pharmaceutical compositions comprising 2-hydroxy-octadecene-9-cis-oate.